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Abstract
Background: Vascular calcification is seen in most patients 
on dialysis and is strongly associated with cardiovascular 
mortality. Vascular calcification is promoted by phosphate, 
which generally reaches higher levels in hemodialysis than 
in peritoneal dialysis. However, whether vascular calcifica-
tion develops less in peritoneal dialysis than in hemodialysis 
is currently unknown. Therefore, we compared coronary ar-
tery calcification (CAC), its progression, and calcification bio-
markers between patients on hemodialysis and peritoneal 
dialysis. Methods: We measured CAC in 134 patients who 
had been treated exclusively with hemodialysis (n = 94) or 
peritoneal dialysis (n = 40) and were transplantation candi-
dates. In 57 of them (34 on hemodialysis and 23 on perito-
neal dialysis), we also measured CAC progression annually 
up to 3 years and the inactive species of desphospho-uncar-
boxylated matrix Gla protein (dp-ucMGP), fetuin-A, osteo-
protegerin. We compared CAC cross-sectionally with Tobit 
regression. CAC progression was compared in 2 ways: with 
linear mixed models as the difference in square root trans-
formed volume score per year (ΔCAC SQRV) and with Tobit 
mixed models. We adjusted for potential confounders. Re-
sults: In the cross-sectional cohort, CAC volume scores were 
92 mm3 in hemodialysis and 492 mm3 in peritoneal dialysis 
(adjusted difference 436 mm3; 95% CI –47 to 919; p = 0.08). 
In the longitudinal cohort, peritoneal dialysis was associated 
with significantly more CAC progression defined as ΔCAC 
SQRV (adjusted difference 1.20; 95% CI 0.09 to 2.31; p = 0.03), 
but not with Tobit mixed models (adjusted difference in CAC 
score increase per year 106 mm3; 95% CI –140 to 352; p = 
0.40). Peritoneal dialysis was associated with higher osteo-
protegerin (adjusted p = 0.02) but not with dp-ucMGP or fe-
tuin-A. Conclusions: Peritoneal dialysis is not associated 
with less CAC or CAC progression than hemodialysis, and 
perhaps with even more progression. This indicates that vas-
cular calcification does not develop less in peritoneal dialysis 
than in hemodialysis. © 2018 The Author(s) 
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Introduction
Cardiovascular disease is the leading cause of death 
among patients with end-stage renal disease [1, 2]. This 
high cardiovascular mortality is strongly associated with 
vascular calcification [3, 4], which occurs frequently [2] 
and progresses almost universally in end-stage renal dis-
ease [5]. Vascular calcification can be measured at various 
sites, such as the coronary arteries, and is promoted by 
phosphate, which is frequently elevated in end-stage re-
nal disease [6, 7].
Remarkably, it is unknown whether vascular calcifica-
tion is affected by dialysis modality, of which the 2 major 
types are hemodialysis and peritoneal dialysis. In theory, 
peritoneal dialysis might induce less vascular calcification 
than hemodialysis because patients on peritoneal dialysis 
generally have lower serum phosphate [8] probably ow-
ing to their continuous clearance. However, there have 
never been randomized studies on this subject, as ran-
domization to dialysis modality is generally refused by 
patients [9]. Moreover, patients on peritoneal dialysis are 
typically younger and healthier due to the prerequisites of 
treatment at home [10], which has hampered previous 
observational research that did not attempt to statistical-
ly adjust for this [11–14].
To overcome this, we compared patients treated with 
hemodialysis or peritoneal dialysis who were all eligible 
for transplantation and thus relatively comparable in age 
and comorbidities. First, we compared coronary artery 
calcification (CAC) cross-sectionally between prevalent 
patients who had been treated exclusively with hemodi-
alysis or peritoneal dialysis. Second, we compared CAC 
progression up to 3 years among those who underwent 
follow-up measurements. Additionally, we studied calci-
fication biomarkers in relation to CAC progression, and 




We analyzed a cross-sectional sample of patients that had been 
treated exclusively with conventional hemodialysis or peritoneal 
dialysis and participated in the NOCTx study. NOCTx 
(NCT00950573) is a prospective nonrandomized study that in-
cluded patients on chronic conventional hemodialysis or perito-
neal dialysis with a minimum dialysis vintage of 2 months, patients 
who switched to nocturnal hemodialysis, and patients who re-
ceived a kidney transplant. Thus, all patients had been treated with 
hemodialysis or peritoneal dialysis at inclusion. Patients were eli-
gible when aged between 18 and 75 years and were candidates for 
transplantation when on dialysis. NOCTx excluded patients with 
a life expectancy < 3 months, non-adherence to dialysis regimens, 
drug abuse, and pregnancy. 
Between December 2009 and February 2016, 329 patients were 
screened for eligibility in 8 Dutch dialysis centers. NOCTx includ-
ed 181 of these patients, of whom 135 were being treated with he-
modialysis and 46 with peritoneal dialysis at inclusion. We exclud-
ed patients who were treated with hemodialysis > 16 h per week 
(n  = 14), as we theorized that more intensive dialysis regimens 
might mitigate calcification. Furthermore, we excluded patients 
who had a history of treatment with the other modality of over 3 
months (n = 33), leaving a sample of 134 patients.
Longitudinal Cohort
We analyzed a longitudinal sample of patients from the NOC-
Tx study who continued treatment with conventional hemodialy-
sis or peritoneal dialysis after inclusion and completed at least one 
follow-up visit (n = 57). In NOCTx, CAC was measured at inclu-
sion, and after 1, 2 and 3 years. Also, blood was collected in 4.5 mL 
potassium-ethylenediaminetetraacetic acid vacutainers (on a non-
dialysis day in case of hemodialysis), immediately centrifuged and 
stored in aliquots at –80  ° C without thawing at inclusion. Patients 
left the study if their renal replacement therapy was changed. 
Treatment Characteristics
Patients were treated according to the Kidney Disease: Improv-
ing Global Outcomes guidelines by the attending nephrologists 
[15]. Hemodialysis was delivered 3 times a week for 4 h with a de-
fault 1.50 mmol/L dialysate calcium concentration, and peritoneal 
dialysis as automatic or continuous ambulant peritoneal dialysis 
with a default 1.25 mmol/L dialysate calcium concentration.
CAC Measurements
We determined CAC scores on nonenhanced, prospectively 
triggered cardiac multi-slice computed tomography (iCT 256, 
Philips Healthcare, Best, The Netherlands). Acquisition parame-
ters were as follows: 120 kV, 40–50 mAs, rotation time 270 ms, and 
128 × 0.625 mm collimation. Metoprolol was administered intra-
venously if heart rate was above 60/min to improve imaging qual-
ity. We used a calcium threshold of ≥130 Hounsfield units. A sin-
gle observer (T.T.J.) read all scans chronologically per patient in 
order to exclude segments with severe motion artefacts or stents at 
a given scan from an entire set. Using commercially available soft-
ware (Heartbeat CS, Philips Healthcare, The Netherlands), we cal-
culated calcium volume scores. Reproducibility of CAC measure-
ments has been shown to be excellent, with an intraclass correla-
tion coefficient of > 0.95 [16].
Calcification Biomarker Measurements
Plasma levels of desphospho-uncarboxylated matrix Gla pro-
tein (dp-ucMGP) were determined as described before [17]. The 
within-run and total variations of this assay were 0.8–6.2% and 
3.0–8.2%, respectively. The assay measuring range was between 
300 and 12,000 pmol/L and was linear up to 11,651 pmol/L [18]. 
The dp-ucMGP assays were performed in a single run by the labo-
ratory of Coagulation Profile, department of Biochemistry, Maas-
tricht, The Netherlands. Plasma fetuin-A and osteoprotegerin lev-
els were measured with a Bio-Plex system (Bio-Rad) multiplex as-
say by the laboratory of the University Medical Center Utrecht, 
Utrecht, The Netherlands. All assays were executed in a single run.
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Other Study Variables
Study personnel recorded demographic and clinical parame-
ters at inclusion (pre-dialysis blood pressure and post-dialysis 
weight averaged from routine measurements during 3 hemodialy-
sis sessions or 2 outpatient visits in case of peritoneal dialysis). 
Laboratory parameters (total calcium, albumin, phosphate, C-re-
active protein, and parathyroid hormone) were obtained at inclu-
sion by averaging routine measurements from 3 months, per-
formed with standard laboratory techniques at the local treatment 
facilities. We classified residual urine production as present (≥100 
mL/24 h) or absent. We defined dialysis vintage as the time be-
tween the first day of dialysis and the day of scanning, minus the 
time with a functioning kidney transplant.
Statistical Analyses
We reported normally distributed variables as mean ± SD, non-
normally distributed variables as median (interquartile range 
[IQR]), and categorical data as number (percentage). We com-
pared normally distributed variables with Student t tests, non-nor-
mally distributed variables with Mann-Whitney-U tests, and cat-
egorical data with chi-square tests.
We compared CAC volume scores cross-sectionally with Tobit 
regression. Tobit regression can be used to analyze variables with 
floor and/or ceiling effects [19]. This may be the case with CAC 
scores, when calcification can be present below the detection limit 
while the CAC score is 0. With Tobit regression, we assume our out-
come variable is actually a normally distributed variable that has 
been truncated (here CAC score truncated at zero). By modeling this 
latent underlying variable, values of zero do not need to be excluded 
from the analyses and do not severely skew the results [19, 20].
To compare CAC progression, we used 2 different approaches, 
since a valid standard method to analyze CAC progression is lack-
ing. First, we analyzed CAC progression with linear mixed models 
as change per year in square root transformed volume scores 
(ΔCAC SQRV). This approach, also known as Hokanson’s method, 
accounts for interscan variability [21] and has been used by others 
[22]. We adjusted these analyses for CAC SQRV at inclusion. Sec-
ond, we used Tobit mixed models to analyze CAC progression. We 
adjusted for factors known to induce calcification [23]: age (years), 
sex (male/female), presence of diabetes mellitus (yes/no), dialysis 
vintage (months), presence of residual urine production ≥100 
mL/24 h (yes/no), and vitamin K antagonist use (yes/no).
We used linear regression to compare biomarker levels be-
tween dialysis modalities. Dp-ucMGP levels were log-transformed, 
as these were right-skewed. We adjusted for potential confounders 
as described above. To determine the relationship between bio-
markers and ΔCAC SQRV between inclusion and 1 year, we cal-
culated Pearson’s correlation coefficients.
We report regression coefficients with 95% CI. We considered 
p values ≤0.05 (2-tailed) statistically significant and used R 3.4.1 (R 
Foundation Statistical Computing) for all analyses.
Results
Cross-Sectional Cohort
The cross-sectional cohort included 134 patients who 
had been treated exclusively with hemodialysis (n = 94) 
or peritoneal dialysis (n = 40). The mean age of this cohort 
was 54 ± 12 years, 94 (70%) were male, median dialysis 
vintage was 17 (IQR 10–34) months, and 24 (18%) had 
diabetes mellitus. The patients on hemodialysis had a me-
dian 6-month longer dialysis vintage, were somewhat 
heavier, had higher blood pressures, and had lower cal-
cium and higher albumin levels than the patients on peri-
toneal dialysis (Table 1). Phosphate levels were not sig-
nificantly higher in the patients on hemodialysis.
CAC volume scores were 92 (IQR 1–663) in the pa-
tients on hemodialysis and 492 (IQR 92–1,139) in the pa-
tients on peritoneal dialysis. The distribution of the CAC 
volume scores is illustrated by a smoothed version of a 
histogram (Kernel density plot) in online supplementary 
Figure S1 (for all online suppl. material, see www.karger.
com/doi/10.1159/000494665). In Tobit regression, the 
CAC volume scores were not significantly (p = 0.15) high-
er in patients on peritoneal dialysis compared to patients 
on hemodialysis (difference 342 mm3; 95% CI –125 to 
808). When adjusted for age, sex, diabetes mellitus, dialy-
sis vintage, residual urine production, and vitamin K an-
tagonist use, peritoneal dialysis was also not significantly 
(p = 0.08) associated with more CAC than hemodialysis 
(difference 436 mm3; 95% CI –47 to 919).
Longitudinal Cohort
The longitudinal cohort included 57 patients treated 
with hemodialysis (n = 34) or peritoneal dialysis (n = 23) 
who completed at least one follow-up visit. The mean age 
of this cohort was 52 ± 13 years, 37 (65%) were male, me-
dian dialysis vintage was 17 (IQR 8–47) months, and 7 
(12%) had diabetes mellitus. The patients on hemodialy-
sis were somewhat heavier, had higher systolic blood 
pressures, tended to have longer dialysis vintages, tended 
to use more vitamin K antagonists, and had lower calcium 
and higher albumin levels than the patients on peritoneal 
dialysis (Table 1), whereas their other characteristics were 
comparable. Notably, CAC volume scores at inclusion 
were not significantly different between patients on he-
modialysis (median 163, IQR 5–745) and patients on 
peritoneal dialysis (median 76, IQR 2–696, p = 0.68), nor 
was the proportion of patients with zero calcification (n = 
8, 24% vs. n = 6, 26%, respectively, p = 0.99). There were 
also no significant differences between the longitudinal 
cohort (n = 57) and those who underwent treatment with 
hemodialysis or peritoneal dialysis after inclusion but did 
not undergo follow-up CAC measurements (online sup-
pl. Table S1).
The maximum follow-up duration was 1 year for 25 pa-
tients, 2 years for 18 patients, and 3 years for 14 patients. 
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CAC progressed in most patients, but only in 2 of 8 patients 
on hemodialysis without CAC at inclusion, and in 2 of 6 
patients on peritoneal dialysis without CAC at inclusion 
(Fig. 1). We analyzed CAC progression as ΔCAC SQRV 
with linear mixed models and with Tobit mixed models.
CAC progressed with 1.72 ΔCAC SQRV per year in 
patients on hemodialysis (95% CI 0.81 to 2.64) and with 
2.73 ΔCAC SQRV per year in patients on peritoneal di-
alysis (95% CI 1.58 to 3.88; Fig. 2). As can be seen in Table 
2, peritoneal dialysis was not significantly (p = 0.18) as-
Table 1. Characteristics of the 134 patients included in the cross-sectional CAC analysis and of the 57 patients included in the CAC pro-
gression analyses, stratified by dialysis modality
Cross-sectional cohort p for 
difference












Demographics and medical history
Age, years 56±11 51±15 0.06 54±12 49±14 0.17
Male, n (%) 62 (66) 32 (80) 0.16 20 (59) 17 (74) 0.37
Body mass index, kg/m2 26.2±4.4 24.7±3.3 0.05 26.7±4.9 24.5±3.4 0.04
Systolic blood pressure, mm Hg 143±20 135±13 0.03 142±20 132±18 0.05
Diastolic blood pressure, mm Hg 79±12 85±10 <0.01 79±11 82±14 0.29
Diabetes mellitus, n (%) 21 (22) 3 (8) 0.07 6 (18) 1 (4) 0.28
Cardiovascular disease, n (%) 23 (25) 10 (25) 0.99 7 (21) 5 (22) 0.99
Current smoker, n (%) 13 (14) 5 (13) 0.99 4 (12) 1 (4) 0.62
History of kidney disease
Dialysis vintage, months 19 (11–35) 13 (7–31) 0.05 26 (10–56) 12 (5–47) 0.06
Cause of end-stage renal disease, n (%) 0.42 0.49
Cystic kidney disease 18 (19) 6 (15) 4 (12) 5 (22)
Interstitial nephritis 5 (5) 1 (3) 2 (6) 1 (4)
Glomerulonephritis 24 (26) 7 (18) 9 (26) 5 (22)
Vascular disease 21 (22) 11 (28) 8 (24) 5 (22)
Diabetic nephropathy 10 (11) 2 (5) 5 (15) 1 (4)
Other 8 (9) 7 (18) 4 (12) 6 (26)
Unknown 8 (9) 6 (15) 2 (6) 0
Dialysis therapy and kidney function
Dialysis therapy
Weekly hemodialysis sessions 3.1±0.5 – 2.9±0.3 –
Weekly hemodialysis hours 11.4±2.0 – 11.0±2.0 –
Daily peritoneal dialysis dwells – 4.4±0.6 – 4.3±0.6
Daily peritoneal dialysis volume, L – 9.8±2.4 – 9.0±2.2
Kidney function
Residual urine production ≥100 mL/24 h n (%) 55 (59) 29 (73) 0.18 20 (59) 14 (61) 0.99
Medication use*
Vitamin K antagonist, n (%) 12 (15) 1 (3) 0.11 7 (21) 0 0.06
Vitamin D analogue, n (%) 61 (75) 32 (89) 0.15 29 (85) 19 (83) 0.99
Calcium-containing phosphate binder, n (%) 28 (35) 14 (39) 0.81 18 (53) 10 (44) 0.67
Cinacalcet, n (%) 16 (20) 7 (19) 0.99 8 (24) 3 (13) 0.52
Laboratory parameters
Calcium, mmol/L 2.3±0.1 2.4±0.1 0.01 2.3±0.1 2.4±0.1 0.01
Albumin, g/L 41.4±3.2 38.3±3.6 <0.001 40.8±3.0 38.5±3.5 0.02
Phosphate, mmol/L 1.6±0.4 1.6±0.4 0.69 1.6±0.3 1.6±0.3 0.50
C-reactive protein, mg/L 3 (2–6) 3 (1–13) 0.93 2 (2–7) 2 (1–18) 0.91
Parathyroid hormone, pmol/L 22 (15–41) 22 (14–37) 0.53 30 (17–48) 22 (15–41) 0.53
Data are presented as mean ± SD, median (IQR) or number (%).* In the cross-sectional cohort, data on medication use were available in 81 patients on hemodialysis and 36 patients on peritoneal dialysis; in the 
longitudinal cohort data on medication use were available in all patients.
CAC, coronary artery calcification.



































































Fig. 1. CAC progression in 57 patients on 
dialysis stratified by dialysis modality, de-
picted as individual trajectories of calcium 
volume scores. Individual trajectories of 
change in calcium volume score in patients 
on hemodialysis (left panel) and patients 
on peritoneal dialysis (right panel). Trajec-
tories of 2 patients on hemodialysis and 
one on peritoneal dialysis with scores > 
5,000 are not shown in this figure. Number 
of patients shown at 0, 1, 2, and 3 years: he-
modialysis 32, 32, 21, and 10; peritoneal di-
alysis: 22, 22, 7, and 4. Note that lines may 
overlap around 0.
Fig. 2. CAC progression per year in 57 pa-
tients on dialysis stratified by dialysis mo-
dality, depicted as boxplots of change in 
square root transformed volume score. 
Change in square root transformed volume 
scores (Y-axis) stratified by dialysis modal-
ity (X-axis) as boxplots. Note that square 
root transformations cannot be back-
transformed. Number of patients per group 
per period (N) denoted below the boxplots. 
Crude P for difference in change in square 
root transformed volume score per year: 
0.18; adjusted P for difference in change in 
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sociated with higher ΔCAC SQRV than hemodialysis in 
unadjusted analyses (difference in ΔCAC SQRV per year 
1.01; 95% CI –0.47 to 2.47). When adjusted for CAC 
SQRV at inclusion, age, sex, diabetes mellitus, dialysis 
vintage, vitamin K antagonist use, and presence of resid-
ual urine production, peritoneal dialysis was significantly 
(p = 0.03) associated with 1.20 ΔCAC SQRV per year 
higher CAC progression compared to hemodialysis (95% 
CI 0.09–2.31). 
In Tobit mixed models, CAC progressed with 99 mm3 
per year in hemodialysis (95% CI –42 to 240) and with 
288 mm3 per year in peritoneal dialysis (95% CI 57 to 
519). As can be seen in Table 2, peritoneal dialysis was not 
significantly associated with higher CAC progression 
than hemodialysis in both crude and adjusted analyses 
with Tobit mixed models (crude difference 189 mm3 per 
year; 95% CI –81 to 459; p = 0.17; and fully adjusted dif-
ference 106 mm3 per year; 95% CI –140 to 352; p = 0.40).
Calcification Biomarkers
At inclusion, we measured calcification biomarkers in 
the longitudinal cohort (n = 57). Dp-ucMGP levels were 
median 1,689 (IQR 1,304–3,470) pmol/L in hemodialysis, 
and 1,548 (IQR 900–1,822) pmol/L in peritoneal dialysis. 
Fetuin-A levels were mean 0.20 ± 0.06 g/L in hemodialy-
sis and 0.21 ± 0.08 g/L in peritoneal dialysis. Osteoprote-
gerin were mean 3.2 ± 1.4 µg/L in hemodialysis and 3.3 ± 
1.2 µg/L in peritoneal dialysis. In univariate analyses, 
peritoneal dialysis was not associated with differences in 
dp-ucMGP, fetuin-A, or osteoprotegerin levels (online 
suppl. Table S2). When adjusted for age, sex, diabetes 
mellitus, dialysis vintage, vitamin K antagonist use, and 
presence of residual urine production, peritoneal dialysis 
was associated with 0.83 µg/L higher osteoprotegerin lev-
els than hemodialysis (95% CI 0.13 to 1.52; p = 0.02), but 
not with differences in dp-ucMGP or fetuin-A. Osteopro-
tegerin correlated with ΔCAC SQRV (Pearson’s correla-
tion coefficient 0.32, p = 0.05), while dp-ucMGP and fe-
tuin-A did not correlate with ΔCAC SQRV (Pearson’s 
correlation coefficients 0.23, p = 0.13; and –0.01, p = 0.93).
Discussion
Our study investigated whether vascular calcification 
develops less in peritoneal dialysis than in hemodialysis, 
cross-sectionally and longitudinally. In a large cross-sec-
tional cohort, we found that patients treated with perito-
neal dialysis do not have less CAC than patients treated 
with hemodialysis. In the longitudinal cohort, we found 
that patients on peritoneal dialysis do not have less CAC 
progression than patients on hemodialysis. Altogether, 
this indicates that vascular calcification does not develop 
less in peritoneal dialysis than in hemodialysis.
Few studies have compared vascular calcification be-
tween hemodialysis and peritoneal dialysis, that is, 3 
cross-sectional studies and one longitudinal study. An 
American cross-sectional study found more frequent 
CAC in pediatric patients on hemodialysis (9/21 patients) 
than on peritoneal dialysis (2/17 patients) [11]. An Alba-
nian cross-sectional study found more frequent cardiac 
valve calcification in adult patients on hemodialysis 
(24/34 patients) than on peritoneal dialysis (10/30 pa-
tients) [12]. A Korean cross-sectional study did not find 
a significant difference in CAC score between patients on 
hemodialysis (n = 31, median score 30) and those on peri-
toneal dialysis (n = 15, median score 16) [13]. Finally, a 
Taiwanese study did not find significant differences in 
Table 2. Effect estimates of CAC progression for peritoneal dialysis (n = 23) compared to hemodialysis (n = 34) 
analyzed with linear mixed models as ΔCAC SQRV and with Tobit mixed models, with different multivariate 
adjustments
Unadjusted CAC SQRV 
at inclusion* Adjustment for age and gender† Full adjustment‡
ΔCAC SQRV 1.01 (–0.47 to 2.47) 1.22 (0.16 to 2.29) 1.25 (0.19 to 2.33) 1.20 (0.09 to 2.31)
Tobit regression 189 (–81 to 459) – 77 (–184 to 338) 106 (–140 to 352)*Tobit mixed models could not be adjusted for CAC SQRV at inclusion.†The linear mixed models of ΔCAC SQRV were additionally adjusted for CAC SQRV at inclusion.‡Full adjustment included age, sex, diabetes mellitus, dialysis vintage, presence of residual urine production, and vitamin 
K antagonist use. The linear mixed models of ΔCAC SQRV were additionally adjusted for CAC SQRV at inclusion
95% CI between brackets.
CAC, coronary artery calcification.
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CAC score or one-year CAC progression between pa-
tients on hemodialysis (n = 18, median score increased 
from 110 to 175) and patients on peritoneal dialysis (n = 
15, median score increased from 3 to 76) [14, 24]. How-
ever, all of these studies had imbalances in age, dialysis 
vintage, or comorbidities between groups, which were 
not adjusted for statistically. In addition, the longitudinal 
study analyzed CAC progression as percentage change, 
which yields biased results because of the skewed distri-
bution of CAC scores with excessive zeros [5]. 
The problematic distribution of CAC scores precludes 
many strategies commonly used to analyze changes. This 
is also why a standard method to analyze CAC progres-
sion is lacking. We therefore chose to analyze CAC pro-
gression with 2 approaches that are valid from a statistical 
viewpoint: as ΔCAC SQRV with linear mixed models and 
with Tobit mixed models. Our data showed a significant 
effect with the former approach that appears larger than 
that with the latter approach. In fact, if we maintained the 
definition of CAC progression ≥2.5 ΔCAC SQRV by Ho-
kanson et al. [21], there would be 6 out of 34 patients on 
hemodialysis with progression and 9 out of 23 patients on 
peritoneal dialysis with progression, implying a number 
needed to harm of 4.7 patients to make one more patient 
progress in CAC on peritoneal dialysis than on hemodi-
alysis. However, this larger effect may be due to modest 
right-skewness of ΔCAC SQRV, despite the square root 
transformation. On the other hand, this larger effect may 
be because Tobit mixed models could not be adjusted for 
CAC score at inclusion. Nevertheless, the estimates from 
both analyses are in the same direction, which support 
our conclusion that peritoneal dialysis is not associated 
with less CAC progression than hemodialysis.
There could be some explanations for our unexpected 
finding that peritoneal dialysis is not associated with less 
CAC or CAC progression. On the one hand, patients on 
peritoneal dialysis may have had a greater time-averaged 
exposure to phosphate than patients on hemodialysis. Af-
ter all, time-averaged phosphate exposure in hemodialy-
sis is lower than suggested by pre-dialysis phosphate lev-
els because of the sawtooth pattern in hemodialysis [25]. 
On the other hand, there could have been differences in 
calcium balance. Patients on hemodialysis might have 
had a positive calcium balance with the default dialysate 
calcium concentration of 1.50 mmol/L based on kinetic 
modeling studies [26], but it is unknown whether patients 
on peritoneal dialysis also had a positive calcium balance 
with a default dialysate calcium concentration of 1.25 
mmol/L, as this also depends on ultrafiltration [27]. This 
would require detailed calcium balance studies. 
Our findings regarding the 3 calcification biomarkers 
do not allow firm conclusions and need further explora-
tion. First, we found that osteoprotegerin was associated 
with progression of CAC, in accordance with previous 
studies [28, 29]. Nevertheless, osteoprotegerin should the-
oretically protect against vascular calcification by prevent-
ing the receptor activator of nuclear factor-κB ligand from 
binding to the RANK receptor [30]. Whether our finding 
indicates a compensatory response requires additional 
study. Second, we did not find a significant association be-
tween CAC progression and dp-ucMGP. Dp-ucMGP is an 
inverse marker of calcification inhibition potential, as its 
active form inhibits vascular calcification after carboxyl-
ation by vitamin K [31]. It is possible that larger samples are 
needed to study the relationship between CAC progression 
and dp-ucMGP. Third, we did not find any relationship 
between fetuin-A and CAC progression. Fetuin-A is a he-
patic protein that forms soluble complexes with calcium 
and phosphate (calciprotein particles [CPPs]) and thus 
prevents calcification [32]. The reason we did not find a 
relationship with CAC progression lies probably in these 
CPPs: an ordinary fetuin-A measurement includes the 
CPP-bound fetuin-A, which is the fetuin-A fraction that 
has already been used up. Future studies should measure 
the non-CPP-bound fraction of fetuin-A after an extra cen-
trifugation step [33], or should measure CPPs directly [34].
Our results should be interpreted within certain limi-
tations. The size of our longitudinal cohort was small and 
patients on peritoneal dialysis had a limited follow-up du-
ration. Larger studies are necessary to investigate wheth-
er peritoneal dialysis may be associated with more CAC 
than hemodialysis and to investigate the relationship be-
tween calcification biomarkers and CAC progression. 
Also, our study was non-randomized, although random-
ization to dialysis modalities has proven infeasible in ear-
lier studies [9]. 
Our study has several strengths as well. This study is 
the largest so far to compare vascular calcification be-
tween hemodialysis and peritoneal dialysis, combining a 
large cross-sectional cohort with follow-up data on pro-
gression of CAC. Also, we accounted for the skewness 
and zero-inflation of CAC scores by using 2 statistically 
valid approaches that enabled essential adjustment for 
potential confounders. Moreover, the patients on hemo-
dialysis and peritoneal dialysis in our study were relative-
ly comparable, as this study only included patients eligi-
ble for transplantation.
In conclusion, peritoneal dialysis is not associated with 
less CAC nor less CAC progression than hemodialysis. 
This indicates that vascular calcification does not develop 
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less in peritoneal dialysis. Further studies should investi-
gate whether vascular calcification develops even more in 
peritoneal dialysis.
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